Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer

Pierre-Étienne Heudel; Sylvie Chabaud; David Pérol; I. Ray-Coquard; Jean Yves Blay

doi:10.1016/j.annonc.2020.09.001

Related publications

Article2023

Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors

Pierre-Étienne Heudel, Anne Montfort, D. Debieuvre, C. Chouaïd, Matthieu Carton, Clarisse Audigier-Valette, Thomas Filleron, Sylvie Chabaud, A. Stancu, Xavier Quantin, Sandrine Hiret, L. Bosquet, Jean Yves Blay

Article2021

Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.

Evangelos Eleutherakis Papaiakovou, Efstathios Kastritis, Flora Zagouri, Dimitra Grapsa, Ioannis Ntanassis-Stathopoulos, Dimitra Stefanou, George Evangelou, Ilias Kotteas, Meletios A Dimopoulos, Konstantinos Syrigos

Article2021

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Pierre-Étienne Heudel, Sylvie Chabaud, David Pérol, Aude Fléchon, Jérôme Fayette, P. Combemale, Olivier Trédan, Françoise Desseigne, Christelle de la Fouchardière, H. Boyle, M. Pérol, Thomas Bachelot, Philippe A. Cassier, Virginie Avrillon, C. Terret, Anne‐Sophie Michallet, Eve‐Marie Neidhardt‐Berard, Emmanuelle Nicolas‐Virelizier, Armelle Dufresne, Amine Belhabri, M. Brahmi, Laure Lebras, Franck E. Nicolini,

Article2025

Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using Real-World Data From the TriNetX Network: Retrospective Cohort Study

Pierre-Étienne Heudel, Gema Hernandez, Olivier Denquin, Hugo Crochet, Jean Yves Blay

Article2021

811 Allelic variation in Human Leukocyte Antigen class II genes is associated with pneumonitis risk in cancer patients treated with immune checkpoint inhibitors

Ashis Saha, Christine N. Spencer, Zia Khan, Jonathan Carroll, Claudia Yanez Arellano, Julie Hunkapiller, Nicholas Bayless, Leonardo Nissola, Roslyn Wallace, Ira Mellman, Rajat Mohindra, Samantha Bucktrout, Shahneen Sandhu, G. Scott Chandler, Christian Hammer, Christian Hammer

Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer

Discussion(0)

Related publications

Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors

Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using Real-World Data From the TriNetX Network: Retrospective Cohort Study

811 Allelic variation in Human Leukocyte Antigen class II genes is associated with pneumonitis risk in cancer patients treated with immune checkpoint inhibitors